GRR1 Antibody

What is GRR1 and what cellular processes does it regulate?

GRR1 (also referred to as Grr1p) functions as an F-box protein component of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex, playing essential roles in protein ubiquitination and subsequent degradation . The protein contains specific functional domains including leucine-rich repeats (LRRs) and an F-box domain, which are critical for its ability to recognize phosphorylated substrates and interact with other SCF complex components, respectively .

Recent research has identified crucial roles for Grr1 in the unfolded protein response (UPR) pathway, specifically in the splicing and translation of HAC1 mRNA . Additionally, Grr1 mediates interactions with phosphorylated forms of G1 cyclins (Cln1 and Cln2), highlighting its importance in cell cycle regulation .

What types of GRR1 antibodies are available for research applications?

Several types of GRR1 antibodies are available for research applications, including:

Most commercial antibodies demonstrate high purity (>95%) and are produced through affinity chromatography purification using specific immunogens .

How should GRR1 antibodies be optimized for Western blotting experiments?

For optimal Western blotting results with GRR1 antibodies, follow these methodological recommendations:

• Dilution optimization: Standard recommended dilutions range from 1:500 to 1:1000, but optimization for your specific experimental conditions is crucial .

• Sample preparation: When investigating Grr1's role in stress responses, consider comparing samples from both stressed and unstressed conditions. For example, studies examining Grr1's role in the unfolded protein response used tunicamycin (Tm) treatment to induce ER stress .

• Detection of mutant variants: When studying Grr1 domain functions, include appropriate controls such as wild-type Grr1, Grr1-ΔN, Grr1-ΔFbox, and Grr1-ΔLRR mutant proteins . This approach enables identification of functionally important domains, as demonstrated in studies showing that F-box and LRR domains are required for downregulation of Ubp3-3HA upon UPR induction .

• Molecular weight verification: Expect to detect Grr1 at its predicted molecular weight, and be aware that post-translational modifications may influence migration patterns.

What are effective immunoprecipitation protocols using GRR1 antibodies?

Effective immunoprecipitation (IP) with GRR1 antibodies requires careful optimization:

• Antibody binding conditions: Incubate cell lysates with 2-5 μg of GRR1 antibody overnight at 4°C with gentle rotation.

• Target enrichment: Based on studies involving Grr1's interaction with phosphorylated substrates, consider phosphatase inhibitor inclusion in lysis buffers to preserve phosphorylation-dependent interactions .

• Verification strategies: When investigating Grr1's interactions with specific substrates (like G1 cyclins), include controls to verify interaction specificity. Studies have shown that the LRR domain is essential for Grr1's ability to bind target proteins, particularly phosphorylated substrates .

• Mutant analysis approach: To dissect domain-specific functions, compare immunoprecipitation results using wild-type Grr1 versus domain deletion mutants (like grr1ΔL, which lacks the LRR domain required for substrate recognition) .

How can researchers investigate GRR1's role in the unfolded protein response (UPR)?

To investigate GRR1's role in the UPR, researchers can employ multiple complementary approaches:

• Gene deletion studies: Compare wild-type cells with grr1Δ mutants during UPR induction. Research has demonstrated that grr1Δ mutants exhibit reduced Hac1p expression upon UPR activation .

• Domain-specific mutant analysis: Express Grr1 variants (Grr1-ΔFbox or Grr1-ΔLRR) in grr1Δ cells to determine which domains are essential for UPR function. Studies have shown these domain mutants confer sensitivity to tunicamycin and reduced Hac1p expression .

• Transcriptome and translatome analysis: Implement RNA-seq and ribosome profiling to assess translational efficiency changes. Research has identified HAC1 as the most significantly translationally upregulated gene during UPR, with approximately 1.96-fold lower translational efficiency in grr1Δ compared to wild-type cells after tunicamycin treatment .

• Splicing efficiency measurement: Quantify HAC1 mRNA splicing, as studies have shown 1.93-fold lower splicing efficiency in grr1Δ mutants (42.5%) compared to wild-type (82.3%) after 4 hours of tunicamycin treatment .

What experimental approaches reveal GRR1's substrate specificity mechanisms?

Investigating GRR1's substrate specificity requires molecular and structural approaches:

• Molecular modeling: Models of Grr1's LRR domain have revealed an unusually high density of cationic charges on the concave surface of its horseshoe-shaped structure, which is important for binding phosphorylated substrates .

• Site-directed mutagenesis: Construct point mutants targeting positively charged residues identified through molecular modeling. Studies have demonstrated these residues are critical for binding phosphorylated G1 cyclins .

• Domain deletion analysis: Generate and express domain deletion constructs (such as grr1ΔL which removes amino acids 447-754 encoding the LRR region) to assess domain-specific functions .

• Protein interaction studies: Employ co-immunoprecipitation with wild-type and mutant Grr1 variants to determine which structural features are required for substrate recognition. Research has confirmed the LRR region is essential for Grr1 function and its ability to bind target proteins .

How can GRR1 antibodies be applied in tracking dynamic protein modifications?

To track dynamic protein modifications of Grr1 and its substrates:

• Time-course experiments: Monitor changes in Grr1-substrate interactions following cellular stress. Studies examining Grr1's role in the UPR showed temporal dynamics of Ubp3-3HA destabilization following tunicamycin treatment was diminished in grr1Δ mutants .

• Phosphorylation-specific detection: Since Grr1 preferentially interacts with phosphorylated substrates, combine GRR1 antibodies with phospho-specific antibodies in sequential immunoprecipitation experiments to enrich for phosphorylated targets.

• Fluorescently conjugated antibodies: Utilize the various available conjugated GRR1 antibodies (Alexa Fluor 488, 555, 594, 647, 680, 750) for live-cell or fixed-cell imaging to track localization changes during cellular responses .

• Mass spectrometry integration: Following immunoprecipitation with GRR1 antibodies, perform mass spectrometry analysis to identify post-translational modifications on Grr1 itself or interacting partners.

What controls should be included when studying GRR1 function in translation regulation?

When investigating GRR1's role in translation regulation, include these essential controls:

• Genetic complementation: In studies with grr1Δ mutants, include complementation with wild-type GRR1 and domain-specific mutants. Research has shown that wild-type Grr1 and Grr1-ΔN, but not Grr1-ΔFbox or Grr1-ΔLRR mutants, can complement the defects in grr1Δ cells .

• Expression level verification: Confirm comparable expression levels of wild-type and mutant Grr1 proteins. Studies have noted that while Grr1-ΔFbox and Grr1-ΔLRR mutants expressed at levels similar to wild-type Grr1, Grr1-ΔN showed significantly lower expression .

• Promoter-specific controls: When studying HAC1 translation, compare HAC1 expressed from its native promoter with expression from heterologous promoters (e.g., TEF1). Research demonstrated that HAC1 mRNAs expressed from the TEF1 promoter showed different responses to tunicamycin treatment in hac1Δ versus grr1Δ hac1Δ cells .

• RNA and protein correlation: Simultaneously measure both mRNA and protein levels, as research has shown cases where Hac1p levels decreased in grr1Δ hac1Δ cells compared to hac1Δ cells despite similar mRNA levels, indicating Grr1's role in facilitating HAC1 mRNA translation independent of ER stress .

How can researchers address background issues when using GRR1 antibodies?

To minimize background and improve specificity with GRR1 antibodies:

• Blocking optimization: Use 5% BSA rather than milk-based blocking agents for phosphorylation-dependent epitopes, as Grr1 recognizes phosphorylated substrates .

• Antibody validation approaches: Validate antibody specificity using grr1Δ mutant cells as negative controls, complemented with various Grr1 domain mutants to confirm epitope recognition patterns .

• Dilution series testing: While recommended dilutions for Western blotting are 1:500~1:1000, immunofluorescence 1:100~1:500, and ELISA 1:10000 , optimize these concentrations for your specific experimental conditions.

• Pre-absorption controls: For polyclonal antibodies, pre-absorb with peptide immunogens when available to confirm specificity of signal.

What are the considerations for cross-reactivity when using GRR1 antibodies across species?

When using GRR1 antibodies across different species, consider:

• Epitope conservation analysis: While many GRR1 antibodies show reactivity against human, mouse, and rat proteins , verify epitope conservation through sequence alignment before cross-species application.

• Validation in target species: Even with predicted cross-reactivity, empirically validate antibody performance in each species using positive and negative controls.

• Domain-specific considerations: For functional studies across species, note that while the F-box and LRR domains are functionally conserved, amino acid sequences may vary, potentially affecting antibody recognition.

• Application-specific optimization: Adjust antibody concentrations and incubation conditions when moving between species, as optimal conditions may differ despite cross-reactivity.